Suppr超能文献

快速准确的贝叶斯诊断肝素诱导的血小板减少症。

Rapid and accurate Bayesian diagnosis of heparin-induced thrombocytopenia.

机构信息

Division of Hematology and Central Hematology Laboratory, Lausanne University Hospital (CHUV) and University of Lausanne (UNIL), Lausanne, Switzerland; and.

Hematology Service, Institut Central des Hôpitaux (ICH), Hôpital du Valais, Sion, Switzerland.

出版信息

Blood. 2020 Apr 2;135(14):1171-1184. doi: 10.1182/blood.2019002845.

Abstract

Prompt diagnostic evaluation of suspected heparin-induced thrombocytopenia (HIT) is critical for guiding initial patient management. We assessed the performance of 3 immunoassays detecting anti-platelet factor 4 (PF4)/heparin antibodies, derived a diagnostic algorithm with a short analytical turnaround time (TAT), and prospectively validated the algorithm. Plasma samples were analyzed by Zymutest-HIA-IgG, HemosIL-AcuStar-HIT-IgG, and ID-H/PF4-PaGIA in retrospective (n = 221) and prospective (n = 305) derivation cohorts. We calculated likelihood ratios of result intervals and cutoff values with 100% negative (NPV) and positive (PPV) predictive values for a positive gold standard functional assay (heparin-induced platelet activation [HIPA]). A diagnostic algorithm was established based on the Bayesian combination of pretest probability and likelihood ratios of first- and second-line immunoassays. Cutoffs with 100% PPV for positive HIPA were >3.0 U/mL (HemosIL-AcuStar-HIT-IgG) and titer ≥16 (ID-H/PF4-PaGIA); cutoffs with 100% NPV were <0.13 U/mL and ≤1, respectively. During the prospective validation of the derived algorithm (n = 687), HemosIL-AcuStar-HIT-IgG was used as unique testing in 566 (82.4%) of 687 cases (analytical TAT, 30 minutes). In 121 (17.6%) of 687 unresolved cases, ID-H/PF4-PaGIA was used as second-line testing (additional TAT, 30 minutes). The algorithm accurately predicted HIT in 51 (7.4%) of 687 patients and excluded it in 604 (87.9%) of 687 patients, leaving only 20 (2.9%) cases unresolved. We also identified 12 (1.7%) of 687 positive predictions not confirmed by HIPA: 10 patients with probable HIT despite negative HIPA and 2 possible false-positive algorithm predictions. The combination of pretest probability with first- and second-line immunoassays for anti-PF4/heparin antibodies is accurate for ruling in or out HIT in ≥95% of cases within 60 minutes. This diagnostic approach improves initial management of patients with suspected HIT.

摘要

对疑似肝素诱导血小板减少症(HIT)进行及时的诊断性评估对于指导初始患者管理至关重要。我们评估了三种检测抗血小板因子 4(PF4)/肝素抗体的免疫测定法的性能,制定了具有较短分析周转时间(TAT)的诊断算法,并前瞻性验证了该算法。通过回顾性(n=221)和前瞻性(n=305)推导队列,用 Zymutest-HIA-IgG、HemosIL-AcuStar-HIT-IgG 和 ID-H/PF4-PaGIA 分析血浆样本。我们计算了结果间隔和截断值的似然比,对于阳性金标准功能测定(肝素诱导血小板活化[HIPA]),这些间隔和截断值的阴性预测值(NPV)和阳性预测值(PPV)均为 100%。基于一线和二线免疫测定法的先验概率和似然比,建立了诊断算法。对于阳性 HIPA,具有 100%PPV 的截断值分别为 >3.0 U/mL(HemosIL-AcuStar-HIT-IgG)和 titer≥16(ID-H/PF4-PaGIA);具有 100%NPV 的截断值分别为 <0.13 U/mL 和≤1。在对推导算法的前瞻性验证(n=687)中,在 687 例病例中的 566 例(82.4%)中仅使用 HemosIL-AcuStar-HIT-IgG 作为唯一检测(分析 TAT,30 分钟)。在 121 例(17.6%)未解决的病例中,作为二线检测使用 ID-H/PF4-PaGIA(额外的 TAT,30 分钟)。该算法在 687 例患者中的 51 例(7.4%)中准确预测了 HIT,并在 687 例患者中的 604 例(87.9%)中排除了 HIT,仅剩下 20 例(2.9%)未解决。我们还发现了 12 例(1.7%)的阳性预测结果未被 HIPA 证实:10 例患者尽管 HIPA 结果为阴性,但仍有疑似 HIT,2 例可能为算法假阳性预测。抗 PF4/肝素抗体的一线和二线免疫测定与先验概率相结合,可在 60 分钟内准确判断 95%以上疑似 HIT 患者的 HIT 阳性或阴性,从而改善疑似 HIT 患者的初始管理。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验